Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: A review article

Climacteric

Volumn 8, Issue 4, 2005, Pages 317-326

  Lakoski, S G ^a   Herrington, D M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

C reactive protein; Coronary heart disease; Estrogens; Hormone therapy; IL 6; SERM

Indexed keywords

C REACTIVE PROTEIN; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYPROTERONE ACETATE; DROLOXIFENE; DYDROGESTERONE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; FENRETINIDE; GESTAGEN; GESTODENE; INTERLEUKIN 6; LEVONORGESTREL; MEDROXYPROGESTERONE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTREL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIMVASTATIN; TIBOLONE;

ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFECT; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; ISCHEMIC HEART DISEASE; MACROPHAGE; MONOCYTE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; T LYMPHOCYTE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; POSTMENOPAUSE; PROGESTINS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 27744573158     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130500345109     Document Type: Review

References (46)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26
2. Hibi M, Nakajima K, Hirano T. IL-6 cytokine family and signal transduction: a model of the cytokine system. J Mol Med 1996;74: 1-12
3. Heinrich PC, Behrmann I, Muller-Newen G, et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334:297-314
4. Castell JV, Gomez-Lechon MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989;242:237-9
5. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102: 2165-8
6. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-4
7. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 2003;58:186-95
8. Ikeda U, Maeda Y, Yamamoto K, et al. C-reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. Cardiovasc Res 2002;56: 86-92
9. Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000;101: 1785-91
10. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3
11. Bermudez EA, Rifai N, Buring J, et al. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002;22:1668-73
12. Cushman M, Meilahn EN, Psaty BM, et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999;19:893-9
13. Barinas-Mitchell E, Cushman M, Meilahn EN, et al. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol 2001;153: 1094-101
14. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002;288: 980-7
15. Manns PJ, Williams DP, Snow CM, et al. Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement. Am J Human Biol 2003;15:91-100
16. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;100:717-22
17. van Baal WM, Kenemans P, van der Mooren MJ, et al. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999;81:925-8
18. Lamon-Fava S, Posfai B, Schaefer EJ. Effect of hormonal replacement therapy on C-reactive protein and cell-adhesion molecules in postmenopausal women. Am J Cardiol 2003;91:252-4
19. Luyer MD, Khosla S, Owen WG, et al. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 2001;86:3629-34
20. Silvestri A, Gebara O, Vitale C, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003;107:3165-9
21. Manning PJ, Sutherland WH, Allum AR, et al. Effect of hormone replacement therapy on inflammation-sensitive proteins in postmenopausal women with Type 2 diabetes. Diabet Med 2002;19:847-52
22. Koh KK, Schenke WH, Waclawiw MA, et al. Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation 2002;105: 1531-3
23. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36:1797-802
24. van Baal WM, Kenemans P, Emeis JJ, et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999;71: 663-70
25. Koh KK, Ahn JY, Jin DK, et al. Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women. Arterioscler Thromb Vasc Biol 2002;22:1459-64
26. Frohlich M, Muhlberger N, Hanke H, et al. Markers of inflammation in women on different hormone replacement therapies. Ann Med 2003; 35:353-61
27. Wakatsuki A, Okatani Y, Ikenoue N, et al. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002; 105:1436-9
28. Yildirir A, Aybar F, Tokgozoglu L, et al. Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels. Gynecol Obstet Invest 2002;53:54-8
29. Skouby SO, Gram J, Andersen LF, et al. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Am J Obstet Gynecol 2002; 186:969-77
30. Stork S, von Schacky C, Angerer P. The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis 2002;165:301-7
31. Goudev A, Georgiev D, Koycheva N, et al. Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women. Maturitas 2002;43:49
32. Lowe GD, Upton MN, Rumley A, et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein-a cross-sectional population survey. Thromb Haemost 2001;86:550-6
33. Modena MG, Bursi F, Fantini G, et al. Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. Am J Med 2002;113:331-4
34. Vongpatanasin W, Tuncel M, Wang Z, et al. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 2003;41:1358-63
35. Lacut K, Oger E, Le Gal G, et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost 2003;90:124-31
36. Zegura B, Keber I, Sebestjen M, et al. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 2003;168:123-9
37. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-25
38. Post MS, van der Mooren MJ, Stehouwer CD, et al. Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial. Thromb Haemost 2002; 88:605-10
39. Fenkci S, Fenkci V, Yilmazer M, et al. Effects of short-term transdermal hormone replacement therapy on glycaemic control, lipid metabolism, C-reactive protein and proteinuria in postmenopausal women with type 2 diabetes or hypertension. Hum Reprod 2003;18: 866-70
40. Sattar N, Perera M, Small M, et al. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet 1999;354:487-8
41. Herrington DM, Brosnihan KB, Pusser BE, et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001;86:4216-22
42. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000; 85:214-8
43. Prelevic GM, Kwong P, Byrne DJ, et al. A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002;77:945-51
44. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-6
45. Oger E, Alhenc-Gelas M, Plu-Bureau, et al. Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy. Time-dependent change in transdermal, but not oral estrogen users. Thromb Res 2001;101:35-43
46. Decensi A, Omodei U, Robertson C, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002;106:1224-8